Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LENZ Therapeutics

Post-Mkt 04-30 19:30:40 EDT

8.98

-0.07

-0.77%

盘后9.25

+0.27+3.01%

19:18 EDT

High9.40	Low8.93	Vol844.30K
Open9.05	D1 Closing9.05	Amplitude5.14%
Mkt Cap280.98M	Tradable Cap140.92M	Total Shares31.29M
T/O7.72M	T/O Rate5.38%	Tradable Shares15.69M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":8.98,"timestamp":1777579200000,"preClose":9.05,"halted":0,"volume":844303,"hourTrading":{"tag":"盘后","latestPrice":9.25,"preClose":8.98,"latestTime":"19:18 EDT","volume":9331,"amount":83868.157051,"timestamp":1777591099632,"change":0.27,"changeRate":0.030067,"amplitude":0.035501},"delay":0,"changeRate":-0.007734806629834285,"floatShares":15692500,"shares":31289969,"eps":-2.85,"marketStatus":"Post-Mkt","change":-0.07,"latestTime":"04-30 19:30:40 EDT","open":9.05,"high":9.395,"low":8.93,"amount":7723547.066914001,"amplitude":0.051381,"askPrice":9.39,"askSize":2000,"bidPrice":9.18,"bidSize":3,"shortable":3,"etf":0,"ttmEps":-2.85,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1777593600000},"marketStatusCode":4,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":9.05,"preHourTrading":{"tag":"盘前","latestPrice":9.04,"preClose":9.05,"latestTime":"09:29 EDT","volume":118,"amount":1068.819987,"timestamp":1777555799999,"change":-0.01,"changeRate":-0.001105,"amplitude":0.040884},"postHourTrading":{"tag":"盘后","latestPrice":9.25,"preClose":8.98,"latestTime":"19:18 EDT","volume":9331,"amount":83868.157051,"timestamp":1777591099632,"change":0.27,"changeRate":0.030067,"amplitude":0.035501},"volumeRatio":1.093557,"impliedVol":1.2533,"impliedVolPercentile":0.9283},"requestUrl":"/m/hq/s/LENZ/tweets","defaultTab":"tweets","newsList":[{"id":"2632866698","title":"Hemab Therapeutics Announces Pricing of Upsized Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2632866698","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632866698?lang=en_us&edition=fundamental","pubTime":"2026-05-01 06:55","pubTimestamp":1777589700,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass. and COPENHAGEN, Denmark, April  30, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/30/3285621/0/en/Hemab-Therapeutics-Announces-Pricing-of-Upsized-Initial-Public-Offering.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPOS","BK4539","BK4007","COAG","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632662706","title":"Oruka Therapeutics Completes Public Equity Offering Under Shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2632662706","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632662706?lang=en_us&edition=fundamental","pubTime":"2026-05-01 05:59","pubTimestamp":1777586362,"startTime":"0","endTime":"0","summary":"An update from Oruka Therapeutics ( ($ORKA) ) is now available. On April 28, 2026, Oruka Therapeutics entered into an underwriting agreement with a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/oruka-therapeutics-completes-public-equity-offering-under-shelf?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/oruka-therapeutics-completes-public-equity-offering-under-shelf?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EQR","BK4539","BK4588","BK4585","LENZ","BK4139","BK4215","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632629316","title":"Transcode Therapeutics files to sell 15.96M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2632629316","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632629316?lang=en_us&edition=fundamental","pubTime":"2026-05-01 05:30","pubTimestamp":1777584652,"startTime":"0","endTime":"0","summary":"17:27 EDT Transcode Therapeutics (RNAZ) files to sell 15.96M shares of common stock for holders Published first on TheFly – the ultimate source for...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/transcode-therapeutics-files-to-sell-15-96m-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/transcode-therapeutics-files-to-sell-15-96m-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LENZ","RNAZ","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632641136","title":"Press Release: Rakovina Therapeutics Inc. Announces 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2632641136","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632641136?lang=en_us&edition=fundamental","pubTime":"2026-05-01 05:17","pubTimestamp":1777583820,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia, April 30, 2026  -- Rakovina Therapeutics Inc.   , a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence -powered drug discovery, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2025, and provided a corporate update.\"Completing the first phase of our restructuring marks an important inflection point for Rakovina,\" said Kim Oishi, CEO of Rakovina. \"Through the recent debenture restructuring, new financing, and the strengthening of our board and executive team, we are well on our way to repositioning the Company for success. As we continue to put our financial house in order, we are sharpening our focus on execution -- advancing our DDR inhibitor pipeline, expanding our strategic partnerships, and unlocking the full potential of our world-class AI-driven drug discovery engine to deliver value for our shareholders.\"","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4543","BK4023","AI","ARTY","BK4555","TM","BK4604","AIYY","BK4528","BK4585","BK4007","03160","BK4539","AIPO","BK4139","BK4551","BK4587","AGIX","CHAT","BK4099","BK4588","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632066100","title":"Summit Therapeutics reports Q1 adjusted EPS (15c), consensus (21c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2632066100","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632066100?lang=en_us&edition=fundamental","pubTime":"2026-05-01 04:53","pubTimestamp":1777582389,"startTime":"0","endTime":"0","summary":"Operational progress continues with ivonescimab (SMT112), an investigational, potentially first-in-class bispecific antibody combining the effects ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/summit-therapeutics-reports-q1-adjusted-eps-15c-consensus-21c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/summit-therapeutics-reports-q1-adjusted-eps-15c-consensus-21c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SMMF","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632666166","title":"Summit Therapeutics Q1 Adj. EPS $(0.15) Beats $(0.18) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2632666166","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632666166?lang=en_us&edition=fundamental","pubTime":"2026-05-01 04:48","pubTimestamp":1777582117,"startTime":"0","endTime":"0","summary":"Summit Therapeutics Q1 Adj. EPS $(0.15) Beats $(0.18) Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/quote/SMMT","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","SMMF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632722666","title":"Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2632722666","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632722666?lang=en_us&edition=fundamental","pubTime":"2026-05-01 04:05","pubTimestamp":1777579500,"startTime":"0","endTime":"0","summary":"Primary and subgroup analysis from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough accepted for oral presentation, including key subgroup analyse","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/30/3285477/0/en/Trevi-Therapeutics-Announces-Oral-Presentation-and-Multiple-Posters-Accepted-at-the-American-Thoracic-Society-ATS-2026-International-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCC","BK4107","FAS","BK4585","BK4117","BK4007","BK4139","AFG","BK4161","BK4588","ATS","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632066645","title":"Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s Ataxia","url":"https://stock-news.laohu8.com/highlight/detail?id=2632066645","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632066645?lang=en_us&edition=fundamental","pubTime":"2026-05-01 04:05","pubTimestamp":1777579500,"startTime":"0","endTime":"0","summary":"BALA CYNWYD, Pa., April  30, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare dise","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/30/3285462/0/en/Larimar-Therapeutics-Publishes-Cross-Species-Findings-Supporting-Skin-as-a-Surrogate-for-the-Measurement-of-Frataxin-in-Tissues-Clinically-Relevant-to-Friedreich-s-Ataxia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FXN","FA","BK4007","LENZ","BK4130","BK4539","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632665889","title":"Bicycle Therapeutics price target lowered to $12 from $13 at Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2632665889","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632665889?lang=en_us&edition=fundamental","pubTime":"2026-05-01 03:56","pubTimestamp":1777579000,"startTime":"0","endTime":"0","summary":"Jefferies analyst Maury Raycroft lowered the firm’s price target on Bicycle Therapeutics (BCYC) to $12 from $13 and keeps a Buy rating on the share...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bicycle-therapeutics-price-target-lowered-to-12-from-13-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bicycle-therapeutics-price-target-lowered-to-12-from-13-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632668120","title":"AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec","url":"https://stock-news.laohu8.com/highlight/detail?id=2632668120","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632668120?lang=en_us&edition=fundamental","pubTime":"2026-05-01 03:00","pubTimestamp":1777575600,"startTime":"0","endTime":"0","summary":"National competition, in collaboration with adMare BioInnovations, demonstrates AbbVie's commitment to a thriving biotech ecosystem in Quebec.Award provides RIME Therapeutics with a year of laboratory","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/30/3285371/0/en/AbbVie-and-adMare-BioInnovations-Announce-RIME-Therapeutics-as-AbbVie-Biotech-Innovators-Award-Recipient-in-Quebec.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089984988.USD","BK4585","XBI","LU1551013425.SGD","IE00B3PB1722.GBP","LU2237443978.SGD","LU0203345920.USD","LU2023251221.USD","IE00BSNM7G36.USD","LU0320765646.SGD","LU0985320562.USD","LU1244550494.USD","IE000BZT7R73.USD","LU0795875169.SGD","IE0002270589.USD","LU0689472784.USD","SG9999015978.USD","RIME","LU1093756168.USD","LU2237443465.HKD","IE0009355771.USD","LU0943347566.SGD","LU0098860793.USD","LU1934455863.HKD","LENZ","BK4550","LU1934455194.USD","IE00BJT1NW94.SGD","IE00BGHQF631.EUR","LU0128525929.USD","LU1003077747.HKD","LU0965508806.USD","BK4534","LU0868494708.USD","LU0708994859.HKD","LU1267930490.SGD","LU2347655156.SGD","LU0689626769.HKD","LU0820561909.HKD","IE00B2B36J28.USD","LU0289961442.SGD","SG9999003800.SGD","ABBV","LU1496350171.SGD","LU0472753341.HKD","IE00BLSP4239.USD","LU0234570918.USD","LU0069063385.USD","LU0289739343.SGD","LU1989772840.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632668638","title":"Hemab Therapeutics 15M share IPO price range $16.00-$18.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2632668638","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632668638?lang=en_us&edition=fundamental","pubTime":"2026-05-01 02:57","pubTimestamp":1777575441,"startTime":"0","endTime":"0","summary":"The deal size was raised to 15M shares from 11.76M shares. Goldman Sachs, Jefferies and Evercore ISI are acting as joint book running managers for ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/hemab-therapeutics-15m-share-ipo-price-range-16-00-18-00-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/hemab-therapeutics-15m-share-ipo-price-range-16-00-18-00-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1894683264.USD","LU1868836914.USD","LU2237438978.USD","IE0002270589.USD","LU2237443382.USD","LU0742534661.SGD","LU2237443622.USD","LU1894683348.USD","LU1868836757.USD","LU2237443465.HKD","SPCX","IE0034235188.USD","BK4127","LU1804176565.USD","LENZ","LU0251142724.SGD","IE0004086264.USD","BK4585","LU1791807156.HKD","BK4539","LU1868836591.USD","BK4516","IPOS","LU2471134879.HKD","IE00B19Z3581.USD","LU0345770308.USD","LU2237443549.SGD","LU2750360641.GBP","BK4007","BK4533","IE00BSNM7G36.USD","LU0251131958.USD","LU0345770993.USD","LU2471134523.USD","LU1868837136.USD","LU1668664300.SGD","LU0106831901.USD","LU2237443895.HKD","LU2471134952.CNY","LU0096364046.USD","LU2237443978.SGD","BK4504","LU0061475181.USD","LU0048573561.USD","LU2750360997.AUD","IE00B19Z3B42.SGD","IE0004091025.USD","LU1868837300.USD","IE00BFXG1179.USD","GSX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631555226","title":"Cadrenal Therapeutics completes CAD-1005 End-of-Phase 2 meeting with FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2631555226","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631555226?lang=en_us&edition=fundamental","pubTime":"2026-04-30 21:59","pubTimestamp":1777557561,"startTime":"0","endTime":"0","summary":"Cadrenal Therapeutics (CVKD) announced a regulatory milestone after completing its End-of-Phase 2 meeting with the FDA and receiving guidance on ke...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cadrenal-therapeutics-completes-cad-1005-end-of-phase-2-meeting-with-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cadrenal-therapeutics-completes-cad-1005-end-of-phase-2-meeting-with-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4585","CVKD","BK4007","BK4588","LENZ","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631065367","title":"Pliant Therapeutics doses first participant in FORTIFY expansion trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2631065367","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631065367?lang=en_us&edition=fundamental","pubTime":"2026-04-30 21:41","pubTimestamp":1777556468,"startTime":"0","endTime":"0","summary":"Pliant Therapeutics (PLRX) announced the dosing of the first participant in the FORTIFY Phase 1b open-label indication expansion clinical trial of ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pliant-therapeutics-doses-first-participant-in-fortify-expansion-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pliant-therapeutics-doses-first-participant-in-fortify-expansion-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","BK4539","LENZ","PLRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631653819","title":"Hemab Therapeutics Boosts IPO to 15 Million Shares from 11.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2631653819","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631653819?lang=en_us&edition=fundamental","pubTime":"2026-04-30 21:34","pubTimestamp":1777556040,"startTime":"0","endTime":"0","summary":"Hemab Therapeutics Holdings has increased the size of its planned initial public offering to 15 million shares from nearly 11.8 million.Hemab on Thursday said it still expects an IPO pricing of $16 to $18 a share.At the $17 midpoint of that range, the Cambridge, Mass., clinical-stage biotechnology company said it now expects net proceeds of about $231.4 million, or around $267 million if the underwriters exercise an option to buy an additional 2.25 million shares.Hemab said its shares have been approved for listing on the Nasdaq Global Select Market under the symbol COAG.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","IPOS","BK4007","BK4139","BK4539","SPCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631658677","title":"Bicycle Therapeutics reports Q1 EPS (87c), consensus (65c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2631658677","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631658677?lang=en_us&edition=fundamental","pubTime":"2026-04-30 21:11","pubTimestamp":1777554680,"startTime":"0","endTime":"0","summary":"Reports Q1 revenue $887k, consensus $7.5M. “The data we reported in the first quarter continues to provide further validation of the potential of o...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bicycle-therapeutics-reports-q1-eps-87c-consensus-65c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bicycle-therapeutics-reports-q1-eps-87c-consensus-65c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631630163","title":"Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2631630163","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631630163?lang=en_us&edition=fundamental","pubTime":"2026-04-30 21:00","pubTimestamp":1777554000,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., April  30, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune dise","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/30/3284944/0/en/Ernexa-Therapeutics-Announces-1-for-25-Reverse-Stock-Split.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ERNA","BK4007","BK4139","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631163202","title":"Press Release: DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2631163202","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631163202?lang=en_us&edition=fundamental","pubTime":"2026-04-30 20:32","pubTimestamp":1777552320,"startTime":"0","endTime":"0","summary":"DiaMedica Therapeutics Inc. , a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke , today announced that its first quarter 2026 financial results will be released after the markets close on Wednesday, May 6 . DiaMedica will host a live conference call on Thursday, May 7 at 8:00 AM Eastern Time / 7:00 AM Central Time to provide a business update and discuss financial results.DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on preeclampsia, fetal growth restriction and acute ischemic stroke. DiaMedica's lead candidate DM199 is the first pharmaceutically active recombinant  form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company's webs","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","DMAC","BK4007","LENZ","AIS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631953637","title":"Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2631953637","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631953637?lang=en_us&edition=fundamental","pubTime":"2026-04-30 20:30","pubTimestamp":1777552200,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., April  30, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics (Nasdaq: PLRX) today announced the dosing of the first participant in the FORTIFY Phase 1b open-label indication ex","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/30/3284839/0/en/Pliant-Therapeutics-Announces-First-Patient-Dosed-in-FORTIFY-the-Phase-1b-Indication-Expansion-Trial-Evaluating-PLN-101095-in-Patients-with-ICI-Refractory-Solid-Tumors.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0456842615.SGD","TME","BK4007","CD","LU0828238088.HKD","BK4023","BK4565","BK4526","LU0359201612.USD","LU0269904917.USD","IE00BYTNYN87.SGD","BK4108","LU0359202008.SGD","SG9999011746.SGD","BK4139","BK4571","BK4548","LU1023057109.AUD","BK4531","IE00B12V2V27.USD","BK4552","01698","BK4563","BK4535","BK4509","IE00BYQNZ168.SGD","LU2039709279.SGD","BK4116","BK4539","LU0509642566.USD","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631637932","title":"Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2631637932","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631637932?lang=en_us&edition=fundamental","pubTime":"2026-04-30 20:30","pubTimestamp":1777552200,"startTime":"0","endTime":"0","summary":"FDA provided critical guidance for the advancement of CAD-1005 to pivotal Phase 3 in HIT Phase 2 data showed a greater than 25% absolute reduction in thrombotic events when CAD-1005 was added to stand","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/30/3284867/0/en/Cadrenal-Therapeutics-Announces-End-of-Phase-2-Meeting-with-the-FDA-and-Pivotal-Phase-3-Registration-Path-for-CAD-1005-in-Heparin-Induced-Thrombocytopenia-HIT.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LENZ","BK4139","ODD","IE0009354923.USD","BK4007","BK4173","BK4183","BK4539","HIT","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631634405","title":"Press Release: Vector Science & Therapeutics Announces Tommy Thompson as Chairman of the Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2631634405","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631634405?lang=en_us&edition=fundamental","pubTime":"2026-04-30 20:12","pubTimestamp":1777551120,"startTime":"0","endTime":"0","summary":"Former Wisconsin Governor and U.S. Secretary of Health and Human Services Brings Extensive Healthcare Leadership to Pioneer of Transdermal Drug Delivery Technology. MEQUON, Wis., April 30, 2026 /PRNewswire/ -- Vector Science & Therapeutics today announced that Tommy Thompson, former Governor of Wisconsin and U.S. Secretary of Health and Human Services, has joined the company as Chairman of the Board.\"We are honored to welcome Tommy Thompson as Chairman of our Board,\" said Bill Jackson, Chief Executive Officer of Vector Science & Therapeutics. \"His unparalleled experience in healthcare policy, combined with his deep understanding of Wisconsin's innovation ecosystem, makes him the ideal leader to guide Vector's strategic direction as we work to bring breakthrough biomechanical and transdermally delivered therapies to clinicians an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VAQC","BK4588","BK4007","BK4539","BK4585","VHT","LENZ","BK4550","BK4561","IXJ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://ir.lenz-tx.com","stockEarnings":[{"period":"1week","weight":-0.0941},{"period":"1month","weight":0.0917},{"period":"3month","weight":-0.491},{"period":"6month","weight":-0.6955},{"period":"1year","weight":-0.6602},{"period":"ytd","weight":-0.4344}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.126},{"period":"3month","weight":0.0253},{"period":"6month","weight":0.0433},{"period":"1year","weight":0.2837},{"period":"ytd","weight":0.0435}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.137955},{"month":2,"riseRate":0.4,"avgChangeRate":0.032476},{"month":3,"riseRate":0.2,"avgChangeRate":-0.143415},{"month":4,"riseRate":0.4,"avgChangeRate":-0.02017},{"month":5,"riseRate":0.25,"avgChangeRate":-0.134416},{"month":6,"riseRate":0.75,"avgChangeRate":0.05507},{"month":7,"riseRate":0.6,"avgChangeRate":0.05308},{"month":8,"riseRate":0.4,"avgChangeRate":0.016536},{"month":9,"riseRate":0.6,"avgChangeRate":0.026875},{"month":10,"riseRate":0.6,"avgChangeRate":-0.067546},{"month":11,"riseRate":0.6,"avgChangeRate":-0.005451},{"month":12,"riseRate":0.4,"avgChangeRate":-0.038411}],"exchange":"NASDAQ","name":"Therapeutics","nameEN":"Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Therapeutics,LENZ,Therapeutics股票,Therapeutics股票老虎,Therapeutics股票老虎国际,Therapeutics行情,Therapeutics股票行情,Therapeutics股价,Therapeutics股市,Therapeutics股票价格,Therapeutics股票交易,Therapeutics股票购买,Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}